- Home
- JMIA vs TSHA Comparison
JMIA vs TSHA Comparison
Compare JMIA & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JMIA | TSHA |
|---|---|---|
| Founded | 2012 | 2019 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | JMIA | TSHA |
|---|---|---|
| Price | $14.26 | $5.27 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $17.00 | $10.56 |
| AVG Volume (30 Days) | 3.1M | ★ 3.4M |
| Earning Date | 02-12-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $173,224,000.00 | $6,310,000.00 |
| Revenue This Year | $20.96 | N/A |
| Revenue Next Year | $22.42 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.60 | $1.05 |
| 52 Week High | $13.92 | $6.02 |
Technical Indicators
Market Signals| Indicator | JMIA | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 66.51 | 49.30 |
| Support Level | $11.48 | $5.58 |
| Resistance Level | $13.55 | $6.02 |
| Average True Range (ATR) | 0.72 | 0.31 |
| MACD | 0.12 | -0.11 |
| Stochastic Oscillator | 92.36 | 36.07 |
Price Performance
Historical ComparisonAbout JMIA Jumia Technologies AG each representing two
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates majority of its revenue from the West Africa segment.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.